Also known tyrosine kinase inhibitor, the Erlocip 100Mg tablet is classified as EGFR/HER1 or epidermal growth factor receptor/human epidermal growth factor receptor type 1. It is indicated for the treatment of pancreatic cancer and non small cell lung cancer that have spread to nearby tissues or to other parts of the body. Recommended in combination with other types of cancer treatments or other medications, this medicine interferes with the protein epidermal growth factor in order to stop it from activating enzymes cancer cells which are required for their multiplication, growth and spread.